What this medicine is commonly used for
Procurement teams reference Teprotumumab when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
Informational only. Treatment decisions belong to qualified clinicians and to local labeling.
Shortage and sourcing context
Demand is concentrated in a small number of specialist centres, and the course structure means orders are planned per patient rather than held as stock. Registration outside its original market is limited, so cross-border requests dominate.
How it is presented
Examples of presentations referenced for this medicine. Actual market presentations vary by country and registration, so check the pack in front of you.
- Powder for concentrate for solution for infusion
Who typically asks us about this medicine
- Patients and families who cannot fill a prescription locally
- Hospital pharmacies managing formulary access during a shortage
- Clinics with defined treatment pathways and continuity of care
- Procurement teams coordinating licensed cross-border sourcing
Full reference text(expand)
Teprotumumab (Tepezza): An IGF-1R inhibiting monoclonal antibody for thyroid eye disease, given as a course of intravenous infusions. Procurement-oriented reference for licensed buyers - not medical advice, and availability depends on region and authorization.
Procurement context
Procurement teams reference Teprotumumab when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
What makes it hard to source
Demand is concentrated in a small number of specialist centres, and the course structure means orders are planned per patient rather than held as stock. Registration outside its original market is limited, so cross-border requests dominate.